BSX — Boston Scientific Corporation

Boston Scientific Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $5.286 billion, representing a 15.9% increase year-over-year, with operational sales growth of 14.3% and organic sales growth of 12.7%.
• Full Year 2025 Revenue: $20.74 billion, a 19.9% increase from 2024, with organic growth of 15.8%.
• Q4 Adjusted EPS: $0.80, up 15% year-over-year, exceeding guidance of $0.77 to $0.79.
• Full Year Adjusted EPS: $3.06, a 22% increase, surpassing the guidance of $3.02 to $3.04.
• Adjusted Operating Margin: 27.3% in Q4 and 28% for the full year, a 100 basis point improvement from 2024.
• Free Cash Flow: $1.13 billion in Q4, totaling $3.659 billion for the year, reflecting 38% growth.

2. Strategic Updates and Business Highlights

• Sales Growth Drivers: Strong performance in Electrophysiology (EP), WATCHMAN, Interventional Oncology (IO), and Endoscopy. EP sales grew 35% in Q4, while WATCHMAN grew 29%.
• Geographic Performance: U.S. operational sales grew 17% in Q4 and 26% for the full year. Asia Pacific saw 15% growth in Q4, driven by Japan and China.
• Acquisitions: Announced agreements to acquire Valencia Technologies and Penumbra, expected to close in 2026, enhancing offerings in urology and cardiovascular segments.
• Product Innovations: Continued investment in new technologies, including the FARAPOINT catheter for AF ablation and expansion of the WATCHMAN portfolio.

3. Forward Guidance and Outlook

• Q1 2026 Guidance: Organic growth expected between 8.5% to 10%, with adjusted EPS guidance of $0.78 to $0.80.
• Full Year 2026 Guidance: Anticipated organic growth of 10% to 11% and adjusted EPS growth of 12% to 14%, with a focus on maintaining strong operational performance.
• Long-term Goals: Commitment to 10%+ organic growth from 2026 to 2028, with 150 basis points of adjusted operating margin expansion.

4. Bad News, Challenges, or Points of Concern

• Market Competition: Concerns about competitive pressures in the EP and WATCHMAN markets, with competitors gaining share. The company anticipates some share loss due to new entrants.
• Product Issues: Noted challenges with the AXIOS device leading to a product removal, which may impact growth in the first half of 2026.
• Geographic Disparities: European growth was slower at 5% in Q4, with supply chain issues affecting performance. The company expects a return to growth in 2026.

5. Notable Q&A Insights

• EP and WATCHMAN Performance: Executives expressed confidence in the growth of EP and WATCHMAN despite sequential flatness in U.S. EP sales. They clarified that the market growth was likely closer to 18%-20% rather than the 25% some analysts projected.
• CHAMPION Trial Expectations: The CHAMPION trial's results are anticipated to strengthen the WATCHMAN indication, with potential for improved adoption rates if positive outcomes are reported.
• Capacity Concerns: Discussions highlighted the need for increased capacity in EP labs to address growing waitlists for procedures, which could impact market growth.
• Future Innovations: Executives emphasized ongoing investments in product development and the importance of new technologies in driving future growth.

This summary encapsulates the key points from Boston Scientific's Q4 2025 earnings call, providing a balanced view of their financial performance, strategic direction, and challenges ahead.